Centre Hospitalier Universitaire de Lille

What Centre Hospitalier Universitaire de Lille does

Centre Hospitalier Universitaire de Lille (CHU de Lille) is a French public university hospital establishment (établissement public de santé) operating under the Code de la Santé Publique and oversight of Agence Régionale de Santé Hauts-de-France. With approximately 16,000 professionals across more than ten specialized sites on a single campus in Lille — including Hôpital Huriez, Hôpital Salengro, Institut Cœur Poumon, Jeanne de Flandre maternity, and Centre Paul Boulanger — it treats roughly 1.4 million patients per year as the referral (recours) and reference center for the Hauts-de-France region in complex pathology, emergency, oncology, rare disease, and maternal/pediatric care. Core clinical and research offerings span ONCOLille (interdisciplinary cancer research institute co-founded with Université de Lille, Inserm, CNRS, and Centre Oscar Lambret, housing 250+ researchers in a 7,000 m2 facility), the CLIP2 early-phase oncology clinical trials center, a rare-disease network of 18 reference centers and 66 competence centers, organ transplantation including first-in-France ex-vivo heart perfusion (OCS), KIDSHEARTS pediatric cardiac surgery, and the largest maternity in mainland France (Jeanne de Flandre, ~5,700 births/year).

Revenue comes primarily from regulated healthcare reimbursements under the French national health insurance system (Sécurité Sociale / Assurance Maladie) via the T2A tariff system, supplemented by competitive research grants (European Union, ANR, PHRC), institutional innovation funding (the Budget Programme Innovation has invested 19M€ over ten years across 103 projects benefiting over 10,000 patients), and donations through the Fonds de Dotation. Distribution operates through direct multi-site hospital care, 24/7 emergency access including SAMU 59 coordination, teleconsultation, professional referral platforms (Hopline phone line, Omnidoc tele-expertise, secure health messaging), and European cross-border referral channels via the EURACAN European Reference Network. The hospital is also a training platform affiliated with Université de Lille, hosting medical education, paramedical schools (écoles paramédicales), and continuing professional development under Qualiopi certification.

Commercial / technology posture is unusual among for-profit-typed entities: CHU de Lille is structurally non-commercial, with no consumer-facing pricing, no M&A history, and no funding rounds. Strategic differentiation rests on regulatory designations (HAS 'Haute qualité des soins' certification at 96%, 16 consecutive years in Le Point magazine's top 3 French hospitals, INCa/ITCC oncology labeling, JACIE hematology accreditation, COFRAC laboratory accreditation, ISO 9001 for research and innovation, ABM/Maastricht III organ procurement), proprietary procedural innovations (MIRO minimally invasive esophageal surgery published in NEJM, acid-resistant IL-2 cytokine engineering published in Science Immunology, OCS heart transplantation, AI-assisted radiology via the Philips Illumeo partnership), and ecosystem integrations with public research bodies and European reference networks that cannot be replicated by competitor centers without equivalent institutional positioning.

Name

Centre Hospitalier Universitaire de Lille

Legal name

Centre Hospitalier Universitaire de Lille

Website

https://chu-lille.fr

Company type

Private

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

CHU de Lille is a French public university hospital employing ~16,000 professionals across a multi-site Lille campus, serving 1.4 million patients annually as the Hauts-de-France reference center for complex, oncology, rare-disease, cardiac, and maternal/pediatric care funded primarily through the Sécurité Sociale reimbursement system.

Ownership category

akta.pro rank

Product category

University Hospital Services

NAICS

General Medical and Surgical Hospitals (622110)

SIC

Services-General Medical & Surgical Hospitals, Nec (8062)

akta.pro primary industry

Community & Regional General Hospitals (HLAFAAAB)

akta.pro secondary industries

Oncology & Cancer Specialty Hospitals (HLAFAHAC), Children’s Hospitals (Acute Care) (HLAFAAAI), Transplant Specialty Hospitals (HLAFAHAE)

Keywords

• University hospital services
• Tertiary healthcare
• Clinical research
• Organ transplantation
• Emergency medical services

Headquarters

HQ city

Lille

HQ country

France

HQ region

Europe

Offices15 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain

Revenue model

1. Public Hospital Healthcare Reimbursements (Sécurité Sociale): CHU de Lille operates as a French public hospital (établissement public de santé) funded primarily through the national health insurance system (Sécurité Sociale). Revenue is generated through patient care billing covered by the French universal health coverage system (Assurance Maladie), supplemented by patient co-payments. As a reference and recourse hospital, it handles the most complex cases.
2. Research Grants and Innovation Funding: Revenue from competitive research grants including European funding (EU programmes), national research agencies (ANR, PHRC), and institutional innovation budgets. The Budget Programme Innovation (BPI) has invested 19 million euros over 10 years supporting 103 projects benefiting over 10,000 patients.
3. Donations and Patronage (Fonds de Dotation): The Fonds de Dotation du CHU de Lille accepts donations and charitable contributions to support medical progress and innovation. Donation pages and fundraising campaigns are operated on the hospital's website.

Pricing tiers

Go-to-market motion1 record

Distribution channels6 records

Marketing channels11 records

Core offering

Centre Hospitalier Universitaire de Lille is a French public university hospital providing tertiary and quaternary patient care, 24/7 emergency services, organ transplantation, oncology treatment, rare disease management, and maternal/pediatric services across multiple hospital sites in Lille. As a recourse and reference hospital for the Hauts-de-France region, it treats approximately 1.4 million patients per year and integrates clinical research, medical education, and innovation activities through partnerships with Université de Lille, Inserm, CNRS, and Centre Oscar Lambret.

Product overview

CHU de Lille is one of Europe's largest university hospital campuses serving approximately 1.4 million patients annually with nearly 16,000 professionals. The institution operates as an integrated healthcare ecosystem comprising multiple specialized institutes and services. Core offerings include ONCOLille (interdisciplinary cancer research institute with 250+ researchers), Institut Cœur Poumon (heart and lung institute with hybrid surgical facilities), CLIP2 early-phase clinical trials center, comprehensive emergency services including SAMU 59, Centre Anti-Poison toxicology services, maternity services at Jeanne de Flandre (largest in mainland France), rare diseases reference center network (18 reference + 66 competence centers), and organ transplantation services. The hospital provides full-service medical imaging with AI-powered diagnostic tools through Philips Illumeo partnership, teleconsultation capabilities, and clinical research participation programs through its Centre d'Investigation Clinique. Patient-facing digital services include IMMUNO TOON educational app, online appointment scheduling, secure medical record uploads, and digital payment systems.

Differentiator

Problem solved

Functional benefit

Brands

• ONCOLille: Interdisciplinary cancer research institute launched by Université de Lille, CHU de Lille, Inserm, CNRS, and Centre Oscar Lambret, focused on understanding cancer mechanisms, treatment resistance, and tumor dormancy.
• Maison des Usagers
• Centre d'Investigation Clinique (CIC)

Products and services

• Emergency Services (URGENCES) and SAMU 59
• Institut Cœur Poumon (Heart and Lung Institute)

Quantifiable outcome

• 1.4 million patients treated annually across all services
• +7 more outcomes

Named customers7 records

Segments7 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability2 records

Feature6 records

Partnerships

22 partnerships are on record, tiered major, core and minor.

• Cliniques universitaires Saint-Luc (Brussels)majorStrategic or Co-development Partner · 1 May 2019KIDSHEARTS project partnership for pediatric cardiac surgery. Enabled the launch of a full pediatric cardiac surgery service in Lille (previously required referral to Brussels). Supported by European INTERREG programme. First operation performed October 15, 2020.
• Université de LillecoreStrategic or Co-development PartnerCHU de Lille operates as the hospital component of the university health campus alongside the Université de Lille. Partnership encompasses medical education (studies, internships, specialty training), joint research (INSERM, CNRS units), and the joint ONCOLille cancer institute. The university and CHU share the campus and collaborate on academic medicine, clinical research, and innovation.
• Institut national du Cancer (INCa)coreStrategic or Co-development PartnerNational cancer institute partnership for the CLIP2 early-phase clinical trials center (one of 7 in France) and the Regional Reference Center in Cancerology - Hauts-de-France. Coordinates NETMESO and Caraderm national networks.
• Centre Oscar Lambret (COL)coreStrategic or Co-development PartnerCHU de Lille and Centre Oscar Lambret jointly operate the Regional Reference Center in Cancerology - Hauts-de-France. They share the CLIP2 early-phase clinical trials center and collaborate on adult and pediatric oncology care. Together they form one of 7 French centers labeled for both adult and pediatric oncology by INCa/ITCC.
• ONCOLillecoreStrategic or Co-development PartnerONCOLille is an interdisciplinary cancer research institute (7,000 m2) co-founded by Université de Lille, CHU de Lille, Inserm, CNRS, and Centre Oscar Lambret. ONCOLille aims to become a national and international reference in cancer research, particularly in treatment resistance and tumor dormancy. Involves over 250 researchers in multidisciplinary approaches including biology, physics, chemistry, mathematics, bioinformatics, health technology, and social sciences.
• InsermcoreStrategic or Co-development PartnerJoint research units and collaborations including CANTHER laboratory (cancer and genome heterogeneity), ONCOLille institute, and multiple other Inserm units hosted or co-affiliated with CHU de Lille. Joint research on immunotherapy, diabetes (EGID), and other biomedical fields.
• CNRScoreStrategic or Co-development PartnerCNRS units collaborate with CHU de Lille through joint research laboratories including CANTHER and ONCOLille. CNRS contributes expertise in biology, chemistry, physics, and computational sciences to the hospital's research ecosystem.
• Inserm, ITCC ConsortiumcoreStrategic or Co-development PartnerITCC (Innovative Therapies for Children with Cancer) consortium partnership for pediatric oncology clinical trials. CHU de Lille and Centre Oscar Lambret are one of 7 French centers labeled by ITCC since 2014 for pediatric oncology research.
• EURACAN (European Rare Cancer Network)coreStrategic or Co-development PartnerEuropean Reference Network (ERN) for rare adult solid cancers. CHU de Lille joined EURACAN on January 1, 2022 as the sole French expert center for rare skin cancers and malignant pleural mesothelioma. Coordinates national INCa Caraderm and NETMESO networks. Part of EU's cross-border healthcare initiative.
• INTERREG (European Programme)majorStrategic or Co-development PartnerEuropean cross-border cooperation programme supporting the KIDSHEARTS project for pediatric cardiac surgery in Lille, in partnership with Cliniques universitaires Saint-Luc de Bruxelles.
• European UnionmajorStrategic or Co-development PartnerEU support for CHU de Lille projects through various programmes including EURACAN (European Reference Network), INTERREG (KIDSHEARTS), and other European research initiatives.
• Agence de la BiomédecinemajorStrategic or Co-development PartnerPartnership for organ and tissue procurement coordination, bone marrow donor registry, and gamete donation. CHU de Lille is certified ABM for organ procurement with Maastricht III authorization for donation after circulatory death.
• Hôpitaux Publics Grand Lille (HPGL)coreStrategic or Co-development PartnerPublic Hospitals Group of Greater Lille (GHT - Groupement Hospitalier de Territoire). CHU de Lille coordinates this hospital group for shared organization, quality certification preparation (synchronized with CHU's HAS certification), and resource optimization across the territory.
• SantélysmajorStrategic or Co-development PartnerHealthcare network based in Eurasanté park, Loos. Santélys partners with CHU de Lille on research awards (annual Appel à Projets Recherche), organ donation conferences, and various healthcare initiatives. Has awarded research prizes to CHU de Lille researchers.
• European Genomic Institute for Diabetes (EGID)majorStrategic or Co-development PartnerEGID is an international research institute focused on diabetes (types 1 and 2), obesity, and associated risk factors. CHU de Lille hosts EGID researchers and collaborates on diabetes research, including COVID-obesity studies and precision medicine approaches.
• MEL (Métropole Européenne de Lille)majorOthersThe Lille European Metropolis is a key institutional partner supporting CHU de Lille through regional development, healthcare planning, and territorial health strategy.
• Région Hauts-de-FrancemajorOthersThe Hauts-de-France region is a major institutional partner and supporter of CHU de Lille's activities and projects.
• Ville de LilleminorOthersThe City of Lille is an institutional partner supporting CHU de Lille through urban planning, public health initiatives, and community events.
• Département du NordminorOthersThe Nord department supports CHU de Lille as a major departmental healthcare institution.
• Agir pour le Cœur des FemmesmajorGTM or Marketing PartnerCo-founded by Pr Claire Mounier-Véhier, cardiologue at CHU de Lille. CHU supports the Bus du Cœur initiative for cardiovascular disease screening in women, especially those in precarious situations. Launched in Lille September 29, 2021, then in 4 other French cities.
• C2DS (Comité de Développement Durable en Santé)minorGTM or Marketing PartnerCHU de Lille is a member and holds the vice-presidency of C2DS, which works to promote health-environment dynamics and sustainable development in healthcare.
• Maison des Parents (Ronald McDonald Foundation)minorGTM or Marketing PartnerRonald McDonald House located near CHU de Lille provides accommodation for families of hospitalized children, offering a home-like environment during treatment.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• AP-HM (Assistance Publique - Hôpitaux de Marseille): Public university hospital group for the Provence-Alpes-Côte d'Azur region with similar tertiary care breadth, ~15,000+ staff, oncology reference centers, and rare-disease activity as CHU de Lille.
• CHU de Toulouse: Regional French university hospital providing tertiary/quaternary care for Occitanie with oncology, transplant, pediatric and rare-disease services comparable to CHU de Lille's regional reference hospital function.
• CHU de Nantes: Western France regional university hospital of comparable size with strong oncology, transplant and rare-disease activity, and an analogous academic medical center model anchored to Université de Nantes.
• CHU de Bordeaux: French regional university hospital serving Nouvelle-Aquitaine with similar multi-site operations, INSERM/CNRS-linked research, and strong oncology and rare-disease reference center activity directly comparable to CHU de Lille.
• Hospices Civils de Lyon: Major French regional university hospital serving Auvergne-Rhône-Alpes with similar reference/recourse role, multi-site campus, integrated research with Université de Lyon, and analogous scope of oncology, transplant, and rare-disease activity.
• CHU de Montpellier: French regional university hospital with comparable scope in oncology, cardiovascular care, rare diseases and clinical research integrated with Université de Montpellier and INSERM.
• CHU de Strasbourg: French regional university hospital with comparable patient volume, multi-specialty reference role, research integration with Université de Strasbourg and IGBMC, and cross-border (Germany/Switzerland) patient flows analogous to CHU de Lille's INTERREG partnerships.

Regional players

• Karolinska University Hospital: Leading Swedish university hospital with comparable academic medical center model, large regional catchment, strong oncology/translation and rare-disease activity serving as Northern Europe's reference site.
• Erasmus MC (Rotterdam): Dutch university hospital of comparable academic standing, oncology and rare-disease research intensity, and Northern-European reference role; analogous in scale to CHU de Lille but serving the Netherlands rather than France.

Broad incumbents

• Assistance Publique - Hôpitaux de Paris (AP-HP): Largest French university hospital network operating ~38 hospitals across the Paris region. Comparable as a public university hospital group (CHU) with research and teaching missions spanning complex care, oncology, rare diseases, and organ transplantation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/CHU_Lille
• YouTubeyoutube.com/channel/UCvB81CdUUKNpaGCTaJFkNVQ
• Facebookfacebook.com/chulille
• LinkedInlinkedin.com/company/chulille
• Instagraminstagram.com/chulille

Compliance15 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Centre Hospitalier Universitaire de Lille